• Ulrich Mrowietz, Felix Lauffer, Wiebke Sondermann, Sascha Gerdes, and Philipp Sewerin.
• Psoriasis Centre at the Department of Dermatology, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel; Department of Dermatology and Allergology, Biederstein, Technical University of Munich; Department of Dermatology, Venereology, Allergology, University Hospital Essen, University Duisburg-Essen, Essen; Rheumatology center of the Ruhr area, Ruhr-University Bochum, Herne.
• Dtsch Arztebl Int. 2024 Jul 12; 121 (14): 467472467-472.

BackgroundPsoriasis was long regarded as an inflammatory disease limited to the skin. Data from dermatologic, rheumatologic and cardiologic research now show it to be a systemic disease, for which the term psoriatic disease is used.MethodsThis paper is based on a selective literature search with special attention to the findings of clinical trials and other current publications, as well as the recommendations of international guidelines.ResultsImmunologically mediated inflammation of the skin, arteries, bones, and joints is a central feature of psoriatic disease. Other diseases that are known to be associated with psoriatic disease include hypertension, metabolic syndrome, and depression. The main risk factor for the development of psoriatic disease is obesity, which also increases the likelihood of psoriatic arthritis. The main known trigger factors are stress, infection, and, less commonly, medication. Psoriatic disease is characterized by complex genetics and by a characteristic pattern of inflammation that involves elements of both innate and acquired immunity and, in particular, the cytokines interleukin 17 and 23. The inflammatory processes underlying psoriatic disease can now be targeted with modern biologic and other therapies.ConclusionIn view of the complexity of psoriatic disease, structured management is now recommended so that physicians and patients can work together to determine the optimal treatment strategy.

15 keywords...

hide…